Merck's Recombivax HB patent
Granted Sept. 6 to the inventors of the vaccine at the University of California, San Francisco and at the University of Washington. Patent covers the hepatitis B surface antigen produced from genetically engineered yeast and the Recombivax HB vaccine. In December 1987, Biogen received a patent covering the manufacture of "all hepatitis B surface and core antigens produced by genetic engineering." Biogen's technology is licensed to SmithKline ("The Pink Sheet" April 11, T&G-4). Merck maintains that any recombinant vaccine for hepatitis B produced through genetically engineered yeast falls under the claims of its patent.
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."